Circassia ditches anti-allergy programme after disappointing results
Neil Woodford-backed Circassia (CIR) has decided to make no further investments in its allergy programmes after its Phase IIb field study failed to meet its primary endpoint. Top-line results from the speciality pharmaceutical...
18 April 2017